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Streptococcus pneumoniae (the pneumococcus) continues to be responsible for a high level of global morbidity and mortality
resulting from pneumonia, bacteremia, meningitis, and otitis media. Here we have used a novel technique involving niche-spe-
cific, genome-wide in vivo transcriptomic analyses to identify genes upregulated in distinct niches during pathogenesis after
intranasal infection of mice with serotype 4 or 6A pneumococci. The analyses yielded 28 common, significantly upregulated
genes in the lungs relative to those in the nasopharynx and 25 significantly upregulated genes in the blood relative to those in the
lungs in both strains, some of which were previously unrecognized. The role of five upregulated genes from either the lungs or
the blood in pneumococcal pathogenesis and virulence was then evaluated by targeted mutagenesis. One of the mutants (malX)
was significantly attenuated for virulence in the lungs, two (aliA andilvH) were significantly attenuated for virulence in the
blood relative to the wild type, and two others (cbiO andpiuA) were completely avirulent in a mouse intranasal challenge
model. We also show that the products of aliA,malX, and piuA are promising candidates for incorporation into multicompo-
nent protein-based pneumococcal vaccines currently under development. Importantly, we suggest that this new approach is a
viable complement to existing strategies for the discovery of genes critical to the distinct stages of invasive pneumococcal disease
and potentially has broad application for novel protein antigen discovery in other pathogens such as S. pyogenes,Haemophilus
influenzae type b, and Neisseria meningitidis.
Streptococcus pneumoniae (the pneumococcus) continues to beresponsible for a high level of global morbidity and mortality,
causing a spectrum of diseases such as pneumonia, bacteremia,
meningitis, and otitis media. In developing countries, up to 1mil-
lion children under 5 years of age die each year from pneumonia,
of which S. pneumoniae is the single commonest cause (30). In
these countries, pneumonia is responsible for 20% of all deaths in
this age group. The prevalence of antibiotic-resistant pneumo-
cocci is increasing rapidly, and vaccination represents the best
prospect for managing pneumococcal disease in the 21st century
(42). However, currently available vaccines are expensive and
have major shortcomings with respect to immunogenicity and/or
strain coverage. Therefore, it is imperative that future decisions
regarding vaccination strategies be based on a deep knowledge of
the complex and dynamic interactions between the pneumococ-
cus and its host.
Asymptomatic colonization of the upper respiratory tract (car-
riage) is an essential first step in the pathogenesis of pneumococcal
disease. Individuals may be colonized by multiple strains or
serotypes of S. pneumoniae, and these presumably compete for
occupation of the nasopharyngeal niche (20). Individuals can be
colonized by pneumococci asymptomatically for many weeks.
However, in a proportion of carriers, the organism is able to pen-
etrate host defenses and cause disease, either by translocation to
sites such as the lungs or middle ear cavity or by direct invasion of
the blood. The precise events associated with progression from
asymptomatic carriage to invasive disease are poorly understood.
The transition involves a major alteration in the microenviron-
ment to which the pneumococcus is exposed, which requires al-
teration in the expression of complex sets of genes. Until recently,
progress on the systematic examination of pneumococcal gene
expression patterns in the distinct environmental nicheswas ham-
pered by technical difficulties associated with isolating sufficient
quantities of pure and intact bacterial RNA from infected host
tissues to perform accurate, quantitative mRNA analyses. To
overcome these difficulties, we pioneered techniques for rapid ex-
traction of bacterial mRNA from infectedmice and demonstrated
that certain pneumococcal virulence-related genes are differen-
tially expressed in vivo and in vitro (33). RNA extraction, enrich-
ment, and linear amplification techniques have been further re-
fined, permitting the first systematic examination of transcription
patterns of key pneumococcal virulence genes in distinct host
niches from the same animal, including sites such as the nasophar-
ynx, where pneumococci exist in very low numbers (19, 22, 31,
35). The results from those studies showed that key pneumococcal
virulence genes were differentially expressed in distinct in vivo
niches, and simultaneous gene expression patterns of selected host
immunomodulatory molecules were also different between host
niches (22). These studies have opened a new vista into the study
of pneumococcal gene expression and innate host responses dur-
ing pathogenesis of invasive disease. Nevertheless, several other
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strategies have also been employed to screen in vivo induced genes
for the discovery and appraisal of novel candidate proteins for
inclusion in a multicomponent pneumococcal protein vaccine
under development. The strategies include, but are not limited to,
in vivo expression technology (IVET) (27), signature-tagged mu-
tagenesis (STM) (12, 18, 44), differential fluorescence induction
(DFI) (4, 23), microarray transcriptomics (40), reverse vaccinol-
ogy (3, 45), antigenome technology (10, 26), genomic array foot-
printing (GAF) (29), and protein expression library screening
(28).
To gain novel insights into global expression of pneumococcal
virulence genes during pathogenesis of invasive disease, we con-
ducted a comprehensive microarray comparison of gene expres-
sion kinetics between pneumococci in the nasopharynx, lungs,
and blood of mice infected with two virulent S. pneumoniae
strains. We hypothesized that progression from carriage to inva-
sive diseasewill require niche-specific alterations in virulence gene
expression and that transcriptomic analysis will identify common
virulence factors critical for disease progression. We also hypoth-
esized that the virulence factors that are upregulated during pro-
gression from carriage to disease, if surface exposed, are likely to
be protective immunogens. Accordingly, we tested and validated
these hypotheses by characterizing the role of these upregulated
genes in pathogenesis using targeted mutagenesis, and we con-
firmed their vaccine potential in mouse challenge models.
MATERIALS AND METHODS
Bacterial strains and growth conditions.The pneumococcal strains used
in this study are serotype 2 (D39), serotype 4 (WCH43), serotype 6A
(WCH16), and their respective isogenic mutant derivatives (Table 1).
Serotype-specific capsule production was confirmed by Quellung reac-
tion, as described previously (5). Opaque-phase variants of the three
strains, selected on Todd-Hewitt broth supplemented with 1% yeast ex-
tract (THY)-catalase plates (50), were used in all animal experiments.
Before infection, the bacteria were grown statically at 37°C in serumbroth
(10% heat-inactivated horse serum in nutrient broth) to an A600 of 0.16
(equivalent to approximately 5 107 CFU/ml).
Mice. Outbred 5- to 6-week-old female CD1 (Swiss) mice, obtained
from the LaboratoryAnimal Services breeding facility of TheUniversity of
Adelaide, were used in all experiments. The Animal Ethics Committee of
The University of Adelaide approved all animal experiments. The study
was conducted in compliance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (7th edition, 2004) and
the South Australian Animal Welfare Act 1985.
Intranasal challenge of mice for gene expression analyses. For each
triplicate WCH16 and WCH43 challenge experiment, groups of 40 mice
were used. The mice were anesthetized by intraperitoneal (i.p.) injection
of pentobarbital sodium (Nembutal; Rhone-Merieux) at a dose of 66 mg
per g of body weight and challenged intranasally (i.n.) with 50 l of bac-
terial suspension containing approximately 1  107 to 2  107 CFU in
serum broth. The challenge dose was confirmed retrospectively by serial
dilution and plating of the inocula on blood agar. In each experiment, at
48, 72, and 96 h postchallenge, at least 12 mice were sacrificed by CO2
asphyxiation, and samples from the nasopharynx, lungs, and blood were
processed as described previously (19, 33). Before processing, lung sam-
ples were further rinsed in 25 ml sterile, ice-cold phosphate-buffered sa-
line (PBS) before homogenization to remove contaminating blood from
the surface. A 40-l aliquot of each sample was serially diluted in serum
broth and plated on blood agar to enumerate pneumococci present in
each niche. Blood plates were incubated at 37°C in 95% air, 5% CO2
overnight. Samples were then stored at 80°C until further processing
was done. The experiment was performed three times for each strain.
Extraction of total RNA from mouse tissues. RNA for microarray
experiments was isolated from the various niches with acid-phenol–chlo-
roform–isoamyl alcohol (125:24:1; pH 4.5; Ambion). Purified RNA sam-
ples were checked for purity and integrity as described previously (19, 22).
Bacterial RNAs from a minimum of five mice that satisfied these criteria
from each specific niche were pooled. The RNA was then purified further
using aQiagenRNeasyminikit. RNAwas further enriched for prokaryotic
RNA using the MicrobEnrich kit (Ambion). The amount of RNA recov-
ered following purification and enrichment was determined by A260/A280
measurements.
Microarray analysis of bacterial RNA.Microarray experiments were
performed on whole-genome S. pneumoniae PCR arrays obtained from
the Bacterial Microarray Group at St George’s Hospital Medical School,
London, England (http://bugs.sghms.ac.uk/). The array was designed us-
ing TIGR4 base strain annotation (49) and extra target genes from strain
R6 (15). The array design is available in BG@Sbase (accession no. A-
BUGS-14; http://bugs.sgul.ac.uk/A-BUGS-14) and alsoArrayExpress (ac-
cession no. A-BUGS-14).
Microarray probes were generated using the 3DNA Array 900 MPX
labeling kit (Genisphere) following the manufacturer’s guidelines. To-
tal amplified RNA of S. pneumoniae obtained from the nasopharynx,
lungs, and blood was used, and pairwise comparisons were made be-
tween the nasopharynx and lung and between the lung and blood RNA
samples from the 48-, 72-, and 96-h time points. RNA samples were
TABLE 1 S. pneumoniae strains used in this study
Strain Description (sequence type) Source or reference
D39 Capsular serotype 2 (595) NCTC 7466
D39::cbiO cbiO deletion mutant of D39 [Eryr] Present study
D39::piuA piuA deletion mutant of D39 [Eryr] Present study
WCH16 Capsular serotype 6A clinical isolate (4966) Women’s and Children’s Hospital, North Adelaide, Australia
WCH43 Capsular serotype 4 clinical isolate (205) Women’s and Children’s Hospital, North Adelaide, Australia
WCH43::adh2 adh2 deletion mutant of WCH43 [Spcr] Present study
WCH43::aliA aliA deletion mutant of WCH43 [Eryr] Present study
WCH43::cbiO cbiO deletion mutant of WCH43 [Eryr] Present study
WCH43::cbpE cbpE deletion mutant of WCH43 [Eryr] Present study
WCH43::cglB cglB deletion mutant of WCH43 [Spcr] Present study
WCH43::dltB dltB deletion mutant of WCH43 [Spcr] Present study
WCH43::ilvH ilvH deletion mutant of WCH43 [Eryr] Present study
WCH43::malX malX deletion mutant of WCH43 [Spcr] Present study
WCH43::nrdD nrdD deletion mutant of WCH43 [Spcr] Present study
WCH43::piuA piuA deletion mutant of WCH43 [Eryr] Present study
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reverse transcribed using Superscript III (Invitrogen) and then labeled
with either Alexa Fluor 546 or Alexa Fluor 647 dye. The fluorescently
labeled cDNAs for each pairwise comparison were then combined and
hybridized to the surface of the microarray, essentially as described
previously (25, 36).
Slides were scanned at 10-m resolution using a Genepix 4000B
scanner (Molecular Devices, USA). Detector photomultiplier tube
(PMT) voltages were adjusted individually for each slide so that the
total red (Alexa Fluor 647) and green (Alexa Fluor 546) fluorescence
signals for each channel were approximately equal while minimizing
the total number of features with signal above the maximum detect-
able. Foreground and background mean pixel intensity values were
extracted from the scanned images for both channels (Alexa Fluor 546,
Alexa Fluor 647) using the Spot plugin (CSIRO, Australia) within the
R statistical software package (http://www.R-project.org). The Limma
plugin for R (47) was used for data processing and statistical analysis.
After background subtraction, the foreground intensities were log2
transformed and a single ratio (Alexa Fluor 647/Alexa Fluor 546) value
was obtained for each probe. Ratio values were normalized using the
print-tip Loess normalization routine (48). The replicate arrays were
normalized to each other to give similar ranges of mRNA expression
values. For each probe across the arrays a linear model was fitted to
determine a final expression value for each mRNA probed and associ-
ated statistics (46). These statistics were used to rank the mRNAs from
those most likely to be differentially expressed to the least likely using
false-discovery rate values of P 0.05. Microarray analysis examining
RNA from infected nasopharynx versus lungs and lungs versus blood
was performed on at least 9 independent hybridizations for each pair-
wise comparison from three separate assays, including at least one dye
reversal per comparison for each strain.
Relative quantitation real-time reverse transcription-PCR (RT-
PCR). For a subset of selected genes that showed significant levels of
upregulation in the lungs or blood by microarray analysis, gene expres-
sionwas validated using SuperScript III one-stepRT-PCRkit (Invitrogen)
in a LightCycler480 II (Roche) as described previously (22). The relative
gene expression was analyzed using the 2CT method (21). The refer-
ence gene was 16S rRNA. The primer pairs used for gene expression anal-
ysis are listed in Table S1 in the supplemental material. All data were
obtained from three biological replicates.
Construction of mutants and assessment of bacterial growth in
vitro.Defined, nonpolar mutants of genes of interest were constructed in
WCH43 (serotype 4) and, for cbiO and piuA mutants, also in D39.
Mutants were constructed by overlap extension PCR as described previ-
ously (14) and validated by PCR and sequencing to be in-frame deletion
mutation replacements. All PCR procedures were performed with the
Phusion High Fidelity kit (FINNZYMES). The primer pairs used for con-
struction and validation of the mutants are listed in Table S2 in the sup-
plemental material. In order to evaluate the growth rate of the mutants in
comparison to the wild type, bacterial strains were grown in serum broth
(SB) and the A600 was monitored overnight on a SpectramaxM2 spectro-
photometer (Millennium Science).
Virulence assessment of mutants. To assess the virulence potential
of mutants, groups of 12 mice were challenged i.n. with approximately
1 107 CFU of either mutant or wild-type bacteria in 50 l SB, under
deep anesthesia. The survival of mice was monitored four times daily
for the first 5 days, twice daily for the next 5 days, and then daily until
21 days after challenge. Differences in median survival times for mice
between groups were analyzed by the Mann-Whitney U test (one and
two tailed).
Competition experiments.Mutant and wild-type strains were grown
separately in SB to an A600 of 0.16 (approximately 5 10
7 CFU/ml). For
each competition experiment, mutant and wild-type bacteria were mixed
at an input ratio of 1:1, and 10 mice were challenged i.n. with 50 l
bacterial suspension containing approximately 1 107 CFU under deep
anesthesia. At 48 h postchallenge, mice from eachmixed-infection exper-
iment were sacrificed, and samples from the nasopharynx, lungs, and
bloodwere processed as described previously (24). A 40-l aliquot of each
sample was serially diluted in serum broth and plated on blood agar and
on blood agar with a selective antibiotic to determine the ratio of mutant
to wild-type bacteria. Competitive indices were calculated as the ratio of
mutant to wild-type bacteria recovered from each niche adjusted by the
input ratio.
Cloning and expression ofHis6-tagged proteins.Based on the results
of the i.n. challenge of mice with gene deletion mutants, the open reading
frame of each gene chosen for further analysis (aliA,malX, and piuA) was
PCR amplified from WCH43 genomic DNA with forward and reverse
primers [aliA: SphI (F), CTACTTTAGCTGCATGCTCTGGATC; SalI
(R), CTTTCTTATATTTGTCGACAGTTATTTCAC;malX: SphI (F), CT
ACACTTGCTAGCATGCTTTTGGTAGCTT; SalI (R), AGGGGGATTT
GATGTCGACCCCCCTTGAAC; piuA: BamHI (F), GCCAGCTTCTGG
ATCCTACTTGGTG; PstI (R), TAAATTGAGTCTGCAGTGGCTTATT
TC], with incorporated restriction sites underlined. Each PCR fragment
was digested with the same enzymes and cloned into the corresponding
restriction sites in either pQE-30 (for aliA) or pQE32 (formalX and piuA)
(Qiagen Inc.) to generate recombinant plasmid constructs. The cloning
and expression of His6-tagged recombinant pneumolysin toxoid (PdT)
was described previously (11). High-level expression of all recombinant
proteins in a lipid A (lpxM) mutant of Escherichia coli BL21(DE3) (9)
transformed with pREP4 (Qiagen) was achieved by induction with 2 mM
isopropyl--D-thiogalactopyranoside (IPTG) for 3 h at 37°C. The cells
were harvested by centrifugation at 6,000 g for 10 min, and the recom-
binant, soluble proteins were purified on a nickel-nitrilotriacetic acid col-
umn essentially as described previously (32). Each protein was judged to
be95% pure by SDS-PAGE and staining with Coomassie brilliant blue
R-250.
Active immunization challenge experiments. For active immuniza-
tion challenge, groups of 5- to 6-week-old female CD1 mice (12 per
group) were immunized i.p. with purified recombinant AliA, MalX,
PiuA, and PdT, in alum adjuvant (Imject Alum no. 77161; Pierce,
Rockford, IL). Each mouse received three doses of 10 g of each anti-
gen in 100 g of alum at 14-day intervals. Mice given the placebo
received an identical course of saline plus alum. Sera were collected
from individual mice by retro-orbital bleeding 1 week after the third
immunization. Antigen-specific enzyme-linked immunosorbent assay
(ELISA) titers were determined as the reciprocal of the dilution of
serum giving 50% of the highest absorbance reading above the back-
ground at 405 nm. Two weeks after the third immunization, mice were
challenged i.p. with approximately 3  104 CFU (in 100 l) of
WCH43. Mice were closely monitored for survival over 21 days. Dif-
ferences in median survival time of mice between groups were ana-
lyzed by the Mann-Whitney U test (one tailed).
Determination of membrane/surface localization.Wild-type WCH43
cells were grown inCYmedium to anA600 of 0.3. After onewash in PBS,
bacteria were resuspended in 50 l of protein-specific polyclonal murine
antisera or anti-alum serum (diluted 1:50, vol/vol), for 30 min at 37°C,
followed by two more washes and then 50 l of Alexa 488 donkey anti-
mouse IgG, heavy and light chain (HL) (Invitrogen; diluted 1:200, vol/
vol) for 1 h on ice. Three replicates for each serum were analyzed using a
BD FACSCanto flow cytometer (BD Biosciences, San Jose, CA) and the
software package Weasel (Walter and Eliza Hall Institute of Medical Re-
search). Data shown are representative of three independent experiments.
Histograms are representative of fluorescence-activated cell sorter
(FACS) data for each protein.
For cell fractionation studies, wild-type WCH43 and its isogenic
aliA, malX, and piuA mutants were grown as described above. Cell
pellets were resuspended in PBS and lysed in a French pressure cell (SLM
Aminco Inc.) at 12,000 lb/in2. Lysates were then subjected to ultracentrif-
ugation at 100,000  g for 1 h to separate soluble (cytoplasmic) and
insoluble (membrane and cell wall) fractions. After several washes in PBS,
pellets containing the insoluble fractions were resuspended in PBS con-
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taining 2% SDS overnight at room temperature. All protein samples were
quantitated by A280 measurements on a NanoDrop 1000 Spectrophoto-
meter (Thermo Scientific). Approximately 50 g of each sample was re-
suspended in sample loading buffer before electrophoresis on a 4 to 12%
Bis Tris NuPAGE gel and then transferred on an iBlot dry blotting (nitro-
cellulose) system (Invitrogen, Life Technologies). After transfer, each
membrane was reacted with a dilution of 1/3,000 polyclonal mouse anti-
AliA,MalX, and PiuA sera, using anti-PsaA as a loading control andmem-
brane compartmentmarker for AliA andMalX blots and anti-AliA serum
as a marker for the PiuA blot. Bound antibodies were detected by using a
1/3,000 dilution of alkaline phosphatase-conjugated goat anti-mouse IgG
(HL) (Bio-Rad) with disodium p-nitrophenylphosphate (Sigma) as the
substrate.
Microarray data accession numbers. Fully annotated microarray
data have been deposited in BG@Sbase (accession number E-BUGS-
133; http://bugs.sgul.ac.uk/E-BUGS-133) and also ArrayExpress (acces-
sion number E-BUGS-133).
RESULTS
Transcriptomic analysis identifies novel, differentially ex-
pressed genes in discrete in vivo niches. Previous mouse intra-
nasal challenge experiments in our laboratory had indicated that
D39 andWCH43 aremore virulent thanWCH16 (A.D.Ogunniyi
and J. C. Paton, unpublished data). Furthermore, after infection
of mice, D39 causes fulminant bacteremia and WCH43 demon-
strates the “classical” disease progression from the nasopharynx to
the lungs, followed by dissemination to the blood and then to the
brain, while WCH16 demonstrates minimal lung and blood in-
volvement before translocation to the brain (22, 39).
The distinct virulence/pathogenic profiles exhibited by WCH16
andWCH43 reflect the spectrumof disease in humans,making these
strains suitable for further analysis. Therefore, bacteria harvested
from the nasopharynx, lungs, and blood of mice at 48, 72, and 96 h
after infection with eitherWCH16 orWCH43, in three replicate ex-
periments, were subjected to pairwise transcriptomic comparisons,
as described inMaterials andMethods. Our analysis shows dramatic
differences in transcript abundance between the two strains. For
WCH16, thecomparisonsyielded253significantlyup-ordownregu-
lated genes in the lungs relative to thenasopharynx (Fig. 1A), and171
genes differentially regulated in the blood relative to the lungs (Fig.
1B). ForWCH43, 315 geneswere differentially regulated in the lungs
relative to the nasopharynx (Fig. 1A), while 370 genes were differen-
tially regulated in the blood relative to the lungs (Fig. 1B).
Further, the genes that were differentially expressed in the dis-
crete in vivo niches of mice infected with either WCH16 or
WCH43 were cross-compared. In this manner, only genes that
were consistently and reproducibly differentially expressed at all
three time points, in all three replicate experiments, and in both
strains were chosen for analysis. The analyses revealed 115 signif-
icantly differentially expressed genes in the lungs versus nasophar-
ynx (Fig. 1A; see Fig. S1 and Table S3 in the supplemental mate-
rial), and 43 differentially expressed genes in the blood versus
lungs (Fig. 1B; see Fig. S2 and Table S3 in the supplemental mate-
rial), common to both strains.We then used an arbitrary cutoff of
1.3-fold regulation for genes for further analysis, as any upregu-
lation below this threshold was not considered to be physiologi-
cally relevant. In so doing, we found 28 genes upregulated in the
lungs compared to the nasopharynx (Table 2) and 25 genes up-
regulated in the blood compared to the lungs (Table 3), common
to both strains. For each pairwise comparison, 8 of the upregu-
lated genes were randomly selected for validation by RT-PCR for
both strains (Tables 2 and 3). Of the 28 genes upregulated in the
lungs compared to the nasopharynx, 18 have been identified in
other screens, and 14 of the 25 genes upregulated in the blood
compared to the lungs have been identified in other screens (Ta-
bles 2 and 3).
Pneumococcal genes upregulated in the lungs and blood
contribute to pathogenesis and virulence.To evaluate the role in
pathogenesis and/or virulence of genes preferentially upregulated
in either the lungs or blood, five genes specifically upregulated in
either niche were subjected to targetedmutagenesis in which each
deleted target gene is replaced by a nonpolar antibiotic resistance
cassette using overlap PCR (seeMaterials andMethods). Selection
criteria included, but were not limited to, in silico bioinformatics
prediction of a role in metabolism, nutrient uptake for survival in
the lungs and/or blood, and putative contribution to pathogene-
sis. The mutation was carried out in WCH43 because it is more
virulent than WCH16. Mutation of the 10 genes chosen for fur-
ther analysis did not adversely affect their growth in vitro in serum
broth (data not shown).
The virulence characteristic of each mutant relative to that of
the isogenic wild-type strain (WCH43) was assessed by intranasal
(i.n.) challenge of mice. In this assay, two of the mutants (cbiO
and piuA) were completely avirulent (Fig. 2). These mutants
were also completely avirulent in this challenge model in a D39
background (not shown). Other mutants, such as the malX,
aliA, and ilvH strains, were also significantly attenuated (Fig.
2). To further examine the contribution of each differentially ex-
pressed gene to pathogenesis, we carried out competition experi-
ments in which groups of mice were challenged i.n. with approx-
imately equal numbers of mutant and wild-type pneumococci.
This enabled evaluation of fine differences between wild type and
mutant by calculating the competitive index for each mutant in
the various niches at 48 h postinfection. The cbiO and piuA
mutants were excluded from this assay because of their complete
FIG 1 Venn diagram of microarray data comparisons of in vivo-expressed
Streptococcus pneumoniae genes. Analysis of interaction of common, differen-
tially expressed genes frommicroarray comparisons of lungs versus nasophar-
ynx (L vsN) (A) and lungs versus blood (L vs B) (B) in WCH16 andWCH43.
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attenuation in the challenge model. Compared to the wild type,
the malX mutant was significantly attenuated in the lungs
(Fig. 3A) and the aliA mutant was significantly attenuated in
the lungs and blood (Fig. 3B), while the ilvH mutant was
significantly attenuated in the blood (Fig. 3C). However, the
numbers of the dltB mutant were not significantly different
from those of the wild type in any of the niches (Fig. 3D). These
results are complementary to the virulence data (Fig. 2), and
they further validate the in vivo transcriptomic approach used
to identify these genes.
Differentially expressed virulence factors are protective
against pneumococcal sepsis. The promising pathogenesis and
virulence data obtained for cbiO, piuA, malX, aliA, and
ilvHmutants led us to carry out in silico bioinformatics analysis
to predict cellular localization. Of the aforementioned factors,
PiuA, MalX, and AliA had signal peptidase II recognition se-
quences and were predicted to be lipoproteins. Accordingly, the
respective recombinant products were expressed and purified as
His6-tagged fusion proteins in E. coli as detailed in Materials and
Methods. Flow cytometry of whole cells with protein-specificmu-
rine polyclonal antisera revealed a very low level of surface expo-
sure of PiuA,MalX, and AliA compared to Pht proteins, which are
known to be exposed on the pneumococcal surface (Fig. 4A and
B). However, the difference in fluorescence for these antigens
compared to negative-control anti-alum serumwas similar to that
of PsaA, a proven lipoprotein and vaccine candidate (25).We then
usedWestern blotting of soluble andmembrane compartments of
fractionated cells (Fig. 4C to E) to show that like PsaA, PiuA,
MalX, and AliA were almost exclusively present in the membrane
fraction.
We then evaluated the potential of purified recombinant PiuA,
MalX, and AliA to protect against fatal sepsis in a mouse intraper-
itoneal (i.p) immunization challenge experiment, using the non-
toxic pneumolysin derivative PdT as a control (see Materials and
Methods). First, we found that strong, antigen-specific antibody
responses were generated in mice to each of the immunogens
(total IgG titer for AliA	 16,000
 1,000, for MalX	 48,000

2,000, for PiuA	 16,000
 1,000, and for PdT	 12,000
 1,000).
Second, we found that mice immunized with recombinant PiuA
or AliA alone were significantly protected against challenge with
WCH43 compared to mice in the placebo group (P 	 0.004 and
P 	 0.010, respectively) (Fig. 5), while protection imparted by
immunization with either MalX or PdT alone was not significant
(P	 0.060 and P	 0.051, respectively).
TABLE 2 Differential gene expression profiles of S. pneumoniae WCH16 and WCH43 in the nasopharynx and lungs of mice by microarray analysis
Gene ID (TIGR4)a Gene annotation
Identified in
previous screensb
Fold change
(lungs/nasopharynx)c
WCH16 WCH43
Sp-0043 Competence factor transport protein ComB Yes (4, 18, 23, 40) 2.0 1.7
Sp-0049 VanZ protein, putative Yes (12) 1.6 (7.7) 1.9 (7.7)
Sp-0202 Anaerobic ribonucleoside triphosphate reductase (NrdD) Yes (40) 2.3 (8.2) 2.0 (7.0)
Sp-0463 Cell wall surface anchor family protein Yes (10) 1.3 1.6
Sp-0545 Immunity protein (BlpY) Yes (40) 1.6 1.8
Sp-0758 PTS system, IIABC components No 1.7 1.7
Sp-0785 HlyD family secretion protein Yes (10, 12) 1.7 (1.8) 2.1 (2.0)
Sp-0787 Antimicrobial peptide ABC transporter permease Yes (40) 1.5 1.8
Sp-0803 Bacterial cell division membrane protein (RodA) No 1.4 1.4
Sp-0804 4-Methyl-5(b-hydroxyethyl)-thiazole monophosphate
biosynthesis protein
No 1.3 1.7
Sp-1083 Putative transcriptional regulator No 1.4 1.5
Sp-1123 Glycogen biosynthesis protein (GlgD) Yes (10) 1.5 2.0
Sp-1368 Psr protein Yes (23) 1.3 1.4
Sp-1382 Cytoplasmic alpha-amylase No 1.6 2.3
Sp-1393 GntR family transcriptional regulator Yes (40) 1.4 1.3
Sp-1395 Phosphate transport system regulatory protein (PhoU) No 1.4 1.5
Sp-1950 Bacteriocin formation protein, putative (CylM protein) No 1.5 (11.6) 2.0 (2.3)
Sp-2026 Bifunctional acetaldehyde-coenzyme A/alcohol
dehydrogenase (Adh2)
Yes (40) 3.6 (8.4) 2.9 (5.6)
Sp-2052 Competence protein CglB Yes (4, 12) 1.7 (18.1) 2.3 (5.8)
Sp-2053 Competence protein CglA Yes (4, 12) 1.4 1.9
Sp-2106 Glycogen phosphorylase family protein No 2.5 3.3
Sp-2107 4-Alpha-glucanotransferase No 2.8 2.8
Sp-2108 Maltose/maltodextrin ABC transporter, maltose/
maltodextrin-binding protein (MalX)
Yes (10, 12, 28) 2.9 (6.8) 3.2 (3.8)
Sp-2109 Maltose/maltodextrin transport system permease protein No 1.7 1.9
Sp-2112 Maltose operon transcriptional repressor (MalR) Yes (40) 1.3 1.8
Sp-2173 DltD protein Yes (40) 1.4 1.5
Sp-2175 DltB protein Yes (12) 1.4 (2.0) 2.1 (15.0)
Sp-2190 Choline binding protein A (CbpA) Yes (12, 40) 1.4 1.7
a Gene IDs were obtained from the S. pneumoniae TIGR4 (serotype 4) genome as deposited in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.
b Reference(s) for previous screens are in parentheses.
c Data in parentheses represent corresponding real-time RT-PCR values for the indicated genes.
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DISCUSSION
The increase in the prevalence of antibiotic-resistant pneumo-
cocci and the existing and emerging shortcomings associated with
current vaccine formulations have underscored the need for alter-
native approaches to management of pneumococcal disease. One
of these strategies involves the development of vaccines based on
pneumococcal proteins that contribute to pathogenesis and are
common to all serotypes, to provide affordable, effective, and
broad protection. Foremost among these antigens are choline
binding protein A (CbpA, also known as PspC or SpsA), pneumo-
coccal surface protein A (PspA), and pneumolysin (Ply) toxoid (2,
41, 43). These proteins have been shown to provide significant
protective immunity alone; theywork in synergy, and they serve as
the gold standard for pneumococcal protein vaccine candidates
(2, 34, 41–43). Nevertheless, protection using the current combi-
nation is by nomeans complete, and protein vaccine formulations
are still being optimized.
An earlier study (40) used either in vitro surrogates for given in
vivo niches (e.g., coculture with Detroit 562 cells in lieu of naso-
pharyngeal colonization; coculture with type II pneumocytes in
lieu of lung infection), or cross-species comparisons of gene ex-
pression between distinct niches (e.g., blood of mice infected with
D39 and adherence assay with Detroit 562 cells using a rough
derivative of TIGR4), neither of which are appropriate models to
investigate pneumococcal pathogenesis. Ourmouse intranasal in-
fection model mimics natural progression of invasive pneumo-
coccal disease in humans, underscoring the superiority of our
technique for identifying novel genes that might be critical to
pneumococcal pathogenesis. The genome-wide transcriptomic
comparisons of gene expression during transition of pneumo-
cocci from the nasopharynx to the lungs, and from there to the
blood in the same animal, provide an alternative approach to
characterizing niche-specific roles of virulence genes during
pathogenesis. Such assessment gives insight into the optimization,
design, and composition of surface protein combinations that
might be more appropriate as vaccine antigens against carriage or
invasive pneumococcal disease.
The analysis of gene expression profiles of pneumococci har-
vested from the nasopharynx compared with expression profiles
of those harvested in the lungs revealed two important observa-
tions. First, the expression of many genes was higher in the naso-
pharynx relative to the lungs for WCH43, consistent with our
previous observation of gene expression profiles of a few selected
pneumococcal virulence proteins in various host tissues (22). It
also provides further molecular evidence in support of the hy-
pothesis advanced by others that many pneumococcal virulence
factors have dual roles in pathogenesis: establishment and main-
tenance of carriage, as well as involvement in certain stages of
invasive disease (6, 12, 13, 38). Second, the relative expression
profiles of many genes of WCH16 in the nasopharynx compared
TABLE 3 Differential gene expression profiles of S. pneumoniae WCH16 and WCH43 in the lungs and blood of mice by microarray analysis
Gene ID (TIGR4)a Gene annotation
Identified in previous
screensb
Fold change (blood/lungs)c
WCH16 WCH43
Sp-0056 Adenylosuccinate lyase Yes (12, 40) 1.5 1.5
Sp-0217 50S ribosomal protein L29 (RpmC) No 1.6 1.7
Sp-0282 PTS system, mannose-specific IID component Yes (18) 1.5 1.3
Sp-0290 Dihydrofolate synthetase Yes (40) 1.4 1.4
Sp-0346 Capsular polysaccharide biosynthesis protein (Cps4A) Yes (40) 1.4 1.7
Sp-0347 Capsular polysaccharide biosynthesis protein (Cps4B) No 1.5 1.8
Sp-0366 Oligopeptide ABC transporter, oligopeptide-binding
protein (AliA)
Yes (18, 40) 1.6 (6.8) 1.4 (5.1)
Sp-0369 Penicillin-binding protein 1A (Pbp1A) Yes (10, 18, 23) 1.8 (2.1) 1.7 (7.0)
Sp-0435 Elongation factor P (EfP) No 1.4 1.3
Sp-0443 Dihydroxyacetone kinase family protein No 1.4 1.8
Sp-0446 Acetolactate synthase 3 regulatory subunit (IlvH) Yes (12, 40) 1.7 (7.5) 1.9 (10.6)
Sp-0447 Ketol-acid reductoisomerase Yes (40) 1.5 2.0
Sp-0448 Hypothetical protein No 1.4 1.9
Sp-0652 SAM-dependent methyltransferase No 1.4 1.8
Sp-0765 DNA polymerase III subunit delta No 1.5 1.6
Sp-0846 Sugar ABC transporter ATP-binding protein No 1.4 1.3
Sp-0930 Choline binding protein E (CbpE) Yes (10, 18) 1.5 (3.8) 1.4 (7.0)
Sp-0989 MutT/nudix family protein; ADP-ribose pyrophosphatase No 1.4 1.3
Sp-1024 Serine hydroxymethyltransferase No 1.5 1.3
Sp-1573 Lysozyme (LytC) Yes (10) 1.6 (3.8) 1.5 (6.7)
Sp-1872 Iron-compound ABC transporter, iron-compound-binding
protein (PiuA)
Yes (12, 18) 1.2 (2.6)d 2.6 (13.1)
Sp-1877 Site-specific tyrosine recombinase XerD-like protein Yes (40) 1.4 1.3
Sp-1939 MATE efflux family protein (DinF) Yes (12) 1.3 (6.7) 2.1 (10.8)
Sp-2009 50S ribosomal protein L33 No 1.5 2.1
Sp-2219 Cobalt/nickel transport system permease protein Yes (18) 1.4 1.3
Sp-2220 Cobalt transporter ATP-binding subunit (CbiO) Yes (18) 1.7 (1.7) 1.6 (10.4)
a Gene IDs were obtained from the S. pneumoniae TIGR4 (serotype 4) genome as deposited in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database.
b Reference(s) for previous screens are in parentheses.
c Data in parentheses represent corresponding real time RT-PCR values for the indicated genes.
d Value did not reach statistical significance by microarray analysis, but genes were significantly upregulated by real-time RT-PCR.
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to the lungs were not as distinct as those seen for WCH43. This is
in concordancewith our previous observation thatWCH16 seems
to progress to the bloodstream with minimal lung involvement
and then to the brain without causing fulminant bacteremia (22).
Mutation in only one of the five pneumococcal genes upregulated
in the lungs—namely, Sp-2108, which encodes the maltose/
maltodextrin-binding protein MalX—resulted in attenuation in
the i.n. challenge model. To corroborate this finding, a mouse
intranasal competition assay with wild-type WCH43 versus its
isogenic malX mutant showed a massive attenuation of the
malXmutant in the lungs but not in the nasopharynx or blood.
Consistent with these findings, MalX was previously identified by
STM as one of the genes essential for lung infection (12). Recent
structural and biochemical analyses have also provided evidence
for a critical role for MalX in the uptake of degradation products
of-glucans, such as glycogen, which is abundant in the lungs (1).
Furthermore, other workers have found antibodies to MalX in
convalescent-phase sera (10), and the protein was recently shown
to be protective against nasopharyngeal colonization through a
TH-17 (IL-17A)-dependent mechanism (28). Thus, we suggest
that MalX is likely to play a role at mucosal surfaces: in nasopha-
ryngeal colonization and in progression to, and in, lung disease.
We also observed that in the transcriptomic comparisons of
lung- versus blood-borne pneumococci, fewer genes were differ-
entially regulated than in the scenario seen for the nasopharynx-
versus-lung comparisons. This strongly suggests limited regula-
tion of pneumococcal gene expression during translocation from
the lungs to the blood. Nevertheless, mutation in four of the five
genes that were significantly upregulated in the blood relative to
the lungs demonstrated either significant (for aliA and ilvH
mutants) or complete (for cbiO and piuA mutants) attenua-
tion relative to the otherwise isogenic wild-type strain WCH43 in
a mouse i.n. challenge model. Significant attenuation of thealiA
andilvHmutants was further confirmed in a mouse i.n. compe-
tition assay, strongly suggesting a requirement for all these genes
for optimal survival of pneumococci in the blood. The significant
attenuation of the aliAmutant in the blood is in contrast to that
observed earlier in a D39 background (17), suggesting a strain-
dependent contribution to virulence.
We then used an active i.p. immunization/challenge experi-
ment to test the hypothesis that surface-accessible virulence fac-
tors that are upregulated in distinct host niches during pathogen-
esis are likely to be protective immunogens. For this purpose, we
chose AliA,MalX, and PiuA for further analysis based on the pres-
ence of signal peptidase II cleavage sites at their N termini. We
were particularly interested in protection against systemic disease,
which is responsible for the significantmortality associatedwith S.
pneumoniae. Significant protection was afforded by immuniza-
tion with AliA and, particularly, with PiuA alone. PiuA is a lipo-
protein first characterized as a highly conserved iron uptake
ATP binding cassette (ABC) transporter required for bacterial
growth and full virulence by Brown et al. (7) following identi-
fication by an STM screen (18). Intraperitoneal immunization
challenge experiments showed that PiuA is protective against
sepsis (8), and passive protection data obtained later confirmed
this to occur via complement-dependent and -independent
bacterial opsonophagocytosis, rather than by inhibition of iron
transport (16). In this study, the level of protection observed
for PiuA is better than what we obtained earlier using D39 as
a challenge strain (8). The difference could be due to a higher
challenge dose used for the D39 experiment but could also be
challenge strain dependent, as we proposed previously (34).
Western blot analysis confirmed that MalX, AliA, and PiuA, like
PsaA, are located in the membrane compartment, as expected for
lipoproteins. Thus, the likely explanation for the observed protection
for PiuA and AliA is that exogenous antibody can penetrate the cap-
sule/cellwall layer to a limited extent andbind the lipoproteins inhib-
iting their biological activity (nutrient transport), rather than pro-
moting opsonophagocytosis. This is in agreementwith the argument
advanced by Whalan et al. for PiuA (51). The fact that labeling by
FACS is very marginal could be due to limited penetration of both
primary antibody aswell as secondary antibody conjugate during the
brief (30-min) incubation period employed. Nevertheless, labeling
with anti-PiuA, anti-MalX, and anti-AliA was significantly greater
than that with the negative-control serum when judged either by
mean fluorescence intensity (Fig. 4B) or percent positive cells (result
not shown).
Although the protection imparted by PdT in this study did not
reach significance, immunization with PdT (or PdB, a similar
pneumolysoid derivative) has been shown to confer protection
against other virulent pneumococci (11, 34), and the protein is
able to synergize with other protective immunogens in systemic
challenge models (32, 34, 37). Given the fact that PiuA provided
solid protection in this study, it would be of interest in a future
study to investigate if a combination of PdT and PiuA would af-
ford superior protection over each antigen alone in a high-dose
challenge model.
FIG 2 Survival times for mice after i.n. challenge with WCH43 and isogenic
mutant derivatives. Groups of 12 or 13 CD1 mice were challenged i.n. with
approximately 1 107 CFU of the indicated strains. Each datum point repre-
sents one mouse. Upward arrows represent cohorts of pneumococcal genes
upregulated in the lungs or blood. The horizontal broken lines denote the
median survival time for each group. *, P  0.05; ***, P  0.001; Mann-
Whitney U test; one and two tailed.
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The current study provides further evidence that PiuA is a valid
vaccine candidate against systemic pneumococcal disease, and it
provides the first evidence that AliA is a promising protein vaccine
candidate against systemic disease as well. We also provide proof-
of-concept data that validate the in vivomicroarray screen used to
identify these promising vaccine candidates. The presence of ele-
vated levels of antibody to PiuA in convalescent-phase sera of
patients with pneumococcal septicemia, and the demonstration
that the immune response elicited is serotype independent (51),
supports this notion. This also strengthens our earlier suggestion
that decisions on the best protein vaccine formulation that would
proceed to clinical trials will require rigorous comparisons of in-
dividual antigens and all possible combinations thereof, using
multiple mouse models and challenge strains (34). A careful ex-
amination of the literature shows that 15 of the 16 randomly se-
lected genes (except the gene forCylMprotein [Sp-1950]) listed in
our analysis were identified by one or more, but not all, of the
current screens for in vivo-expressed genes. This indicates that no
single screening method is necessarily a stand-alone procedure
but argues strongly in favor of our technique as valid,more robust,
andmore comprehensive, since it identifiedmore candidate genes
than other studies. Our technique also offers the advantage that it
is less laborious and identifies key genes that are critical (either for
survival or virulence) at each stage of the disease process. The
screen also identified several other potentially interesting genes
upregulated in discrete niches (at least 10 in the lungs and 8 in the
blood) that are yet to be evaluated for their role in pathogenesis,
and this presents avenues for future work. Such work would in-
volve a thorough characterization of the critical regulatory path-
ways employed by the pneumococcus in discrete in vivo niches
in accordance with host factors, nutrient availability, etc., and
deployment of primary virulence determinants in those niches,
leading to an improved understanding of pneumococcal
pathogenesis, and potentially, identification of novel targets
FIG 3 Competition experiments between wild-type WCH43 and its isogenic mutants in the nasopharynx, lungs, and blood of mice at 48 h postinfection. (A)
Wild type versusmalXmutant; (B) wild type versusaliAmutant; (C) wild type versusilvHmutant; (D) wild type versusdltBmutant. Ten CD1mice were
infected i.n. with equal numbers (approximately 1  107 CFU each) of wild type and mutant in each experiment. Each datum point represents the ratio of
recoveredmutant bacteria to wild-type bacteria. The horizontal solid line represents a 1:1 ratio of recoveredmutant bacteria. The horizontal broken line denotes
the geometric mean value of the ratio of recovered mutant bacteria for each comparison. *, P 0.05; ***, P 0.001; one sample t test; two tailed.
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FIG 4 Membrane/surface localization studies. (A) Histograms showing marginal surface labeling of lipoproteins AliA, MalX, PiuA, and PsaA but substantial
labeling of surface-localized PhtABDE with respective antisera. (B) Mean fluorescence data for AliA, MalX, PiuA, PsaA, and PhtABDE labeling with respective
antisera, using alum-immunized serum as a negative control (**, P 0.01; ***, P 0.0001; unpaired t test; one tailed). (C, D, and E), Western blots of soluble
(S) and membrane (M) fractions of S. pneumoniae WCH43 and its isogenic aliA (C), malX (D), and piuA (E) mutants showing the reactivities of the
antibodies raised against the various protein antigens. The samples were reactedwith specific antisera generated frommice immunizedwith the various antigens;
PsaA was used as a loading control andmembrane compartment marker for AliA andMalX blots, and AliA was used as a marker for the PiuA blot. The expected
mobilities and molecular mass of each test and marker protein are also indicated.
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for intervention. We also propose that identification of the best
candidates for an optimal pneumococcal protein vaccine for-
mulation is likely to require a combination of existing and
novel strategies (such as the one used in this study) used for
antigen discovery. The in vivo transcriptomic technique de-
scribed here could also be easily applied to novel antigen dis-
covery in other pathogens such as S. pyogenes, Haemophilus
influenzae type b, and Neisseria meningitidis.
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